Trends of the WorldCRISPR Gene Editing Breakthrough
Laboratory-evolved CRISPR-associated transposases enabling programmable gene insertion represent a fundamental leap beyond standard CRISPR editing, potentially solving off-target and double-strand break limitations for therapeutic gene therapy.
This is one of 6 signals scored across 21 industries in our latest scan.
See them all free →Since we flagged this
First flagged
25 March 2026 · score 9.0/10
Score trajectory (10 runs, live record)
Corroborating sources since flagging
153
The signal strengthens if
- A Phase 2 trial enrolling at least 100 patients with lipid disorders reports LDL reductions of 40% or greater sustained beyond 18 months with no treatment-related serious adverse events.
- A second independent clinical site publishes replication data showing comparable LDL and triglyceride reductions from a single CRISPR-Cas9 infusion in a medication-resistant lipid disorder cohort.
The signal weakens if
- Follow-up beyond 12 months in the current Phase 1 cohort shows significant LDL rebound to within 20% of baseline, indicating loss of durable editing effect.
- A serious adverse event attributable to off-target CRISPR editing is reported in this or a directly analogous in-vivo liver-targeting trial within the next 24 months.
Mainstream coverage followed 26 days later — first coverage.
How the evidence accumulated
CRISPR Gene Editing Breakthrough
Since 25 March 2026
How the evidence accumulated — 14 findings and 153 corroborating sources since 25 March 2026.
Create a free account to see the timeline.
Create free accountScores are model-generated assessments of accumulated evidence and may be incomplete or wrong. Provided for informational purposes only; not investment advice.
Sources
Scored from 14 independent sources.
Members also get the underlying papers and reports, the related news feed and the regulatory register for this industry. Open the sources free →
More in Biotech
Other trends the engine is currently tracking in this industry.
- mRNA Vaccine Platform Expansion6.0/ 10 · 8 signals
- Digital Therapeutics FDA Approval7.0/ 10 · 1 signal
- GLP-1 Obesity Drug Development7.0/ 10 · 8 signals
- Lab Grown Meat Commercialization6.7/ 10 · 6 signals
- Synthetic Biology Industrial Applications6.6/ 10 · 5 signals
- Brain Computer Interface Technology8.5/ 10 · 4 signals
Start reading the full feed
A weekly sample of what the engine finds.
- 3 scored signals per week, sources included — no card required
- Preview of top trends
- Basic industry labels
- Sunday Signals (weekly) teaser
Disclaimer: The information provided on this page is for educational and informational purposes only. It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities. Stock data shown is illustrative and may not reflect real-time prices. Always conduct your own research and consult a qualified financial advisor before making investment decisions. Past performance does not guarantee future results.